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OBJECTIVES The goal of this study was to evaluate combinations of eptifibatide with reduced-dose
tenecteplase (TNK) in ST-elevation myocardial infarction (STEMI).
BACKGROUND Glycoprotein IIb/IIIa inhibitors enhance thrombolysis. The role of combination therapy in
clinical practice remains to be established.
METHODS Patients (n  438) with STEMI 6 h were enrolled. In dose-finding, 189 patients were
randomized to different combinations of double-bolus eptifibatide and reduced-dose TNK.
In dose-confirmation, 249 patients were randomized 1:1 to eptifibatide 180 g/kg bolus, 2
g/kg/min infusion, and 180 g/kg bolus 10 min later (180/2/180) plus half-dose TNK (0.27
mg/kg) or standard-dose (0.53 mg/kg) TNK monotherapy. All patients received aspirin and
unfractionated heparin (60 U/kg bolus; infusion 7 U/kg/h [combination], 12 U/kg/h
[monotherapy]). The primary end point was Thrombolysis In Myocardial Infarction (TIMI)
grade 3 epicardial flow at 60 min.
RESULTS In dose-finding, TIMI grade 3 flow rates were similar across groups (64% to 68%). Arterial
patency was highest for eptifibatide 180/2/180 plus half-dose TNK (96%, p  0.02 vs.
eptifibatide 180/2/90 plus half-dose TNK). In dose-confirmation, this combination, com-
pared with TNK monotherapy, tended to achieve more TIMI 3 flow (59% vs. 49%, p 
0.15), arterial patency (85% vs. 77%, p  0.17), and ST-segment resolution (median 71% vs.
61%, p  0.08) but was associated with more major hemorrhage (7.6% vs. 2.5%, p  0.14)
and transfusions (13.4% vs. 4.2%, p 0.02). Intracranial hemorrhage occurred in 1.0%, 0.6%,
and 1.7% of patients treated with any combination, eptifibatide 180/2/180 and half-dose
TNK, and TNK monotherapy, respectively.
CONCLUSIONS Double-bolus eptifibatide (180/2/180) plus half-dose TNK tended to improve angiographic
flow and ST-segment resolution compared with TNK monotherapy but was associated with
more transfusions and non-cerebral bleeding. Further study is needed before this combination
can be recommended for general use. (J Am Coll Cardiol 2003;41:1251–60ii) © 2003 by
the American College of Cardiology Foundation
Goals of pharmacologic reperfusion regimens in ST-
elevation myocardial infarction (STEMI) include reestab-
lishing rapid antegrade flow in the infarct artery, restoration
of myocardial tissue level reperfusion, and maintenance of
epicardial arterial patency (1). Several previous phase II
angiographic studies (2–5), and most recently two larger
clinical trials (6,7) have studied combinations of intravenous
platelet glycoprotein IIb/IIIa inhibitor and reduced-dose
See page 1261
fibrinolytic with the hope that the addition of a potent
platelet inhibitor might overcome the failure of reperfusion
that can occur with fibrinolytic monotherapy (8). Chal-
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lenges to this approach to date include complex adminis-
tration regimens, unclear relationship between surrogate
markers of efficacy and clinical benefit, and increased risks of
hemorrhage, thrombocytopenia, and transfusions.
Two previous studies of eptifibatide in combination with
alteplase (5,9) demonstrated improvements in Thrombolysis
In Myocardial Infarction (TIMI) grade 3 flow compared
with alteplase monotherapy. However, the doses of eptifi-
batide studied and the use of alteplase in these two trials
may not represent the optimal combination of eptifibatide
and fibrinolytic (10–12). Furthermore, alteplase is more
cumbersome to administer and is associated with more
non-cerebral bleeding than single-bolus tenecteplase (TNK)
(13). The Integrilin and Tenecteplase in Acute Myocardial
Infarction (INTEGRITI) trial sought to evaluate dosing
combinations of double-bolus eptifibatide with reduced-
dose TNK in patients with acute STEMI.
METHODS
In this phase II angiographic open-label study, patients
were enrolled at 67 hospitals in seven countries between
May 2000 and August 2001. The trial was supported by
central units and core laboratories as described in the
Appendix.
Eligibility criteria. The inclusion criteria were ischemic
discomfort for at least 30 min with onset 6 h, along with
electrocardiographic criteria of STEMI (14) in patients age
18 to 75 years. All patients signed written informed consent
approved by the local institutional review board/ethics
committee.
Key exclusion criteria (14) were as follows: uninterpret-
able ST-segments, active bleeding or increased risk of
bleeding; previous coronary artery bypass graft surgery
(CABG); cardiogenic shock or pulmonary edema requiring
intubation; blood pressure 180 mm Hg systolic or 110
mm Hg diastolic; known hypersensitivity to any study
regimen component; creatinine 4.0 mg/dl; other serious
illness; and inability to comply with the protocol.
Randomization. Patients were randomized using a central,
computerized, telephone randomization system (CTS
Durham, Durham, North Carolina). Randomization was
stratified by infarct location (anterior vs. non-anterior), and
treatments were open-label. In dose-finding, all patients
received the combination of eptifibatide and reduced-dose
TNK, whereas in dose-confirmation patients were random-
ized 1:1 to either combination therapy or TNK mono-
therapy (Fig. 1).
Treatment regimens. All patients received aspirin (162 to
325 mg oral or 150 to 500 mg intravenous) followed by daily
oral aspirin. The unfractionated heparin bolus dose was 60
U/kg (maximum 4,000 U) in all patients (15). Patients
assigned to combination therapy with eptifibatide and TNK
received a reduced heparin infusion of 7 U/kg/h (maximum
800 U/h), whereas patients assigned to TNK monotherapy
received the heparin infusion of 12 U/kg/h (maximum 800
U/h) (15). A nomogram was used to target the activated
partial thromboplastin time (aPTT) to 1.5 to 2.5 times
control.
Abbreviations and Acronyms
aPTT  activated partial thromboplastin time
CABG  coronary artery bypass graft surgery
cTFC  corrected Thrombolysis In Myocardial
Infarction frame count
ICH  intracranial hemorrhage
INTEGRITI  Integrilin and Tenecteplase in Acute
Myocardial Infarction trial
MI  myocardial infarction
PCI  percutaneous coronary intervention
STEMI  ST-elevation myocardial infarction
TIMI  Thrombolysis In Myocardial Infarction
TMPG  Thrombolysis In Myocardial Infarction
myocardial perfusion grade
TNK  tenecteplase
Figure 1. Study schema. In dose-finding Part 1 (top, A), all patients
received the same double-bolus regimen of eptifibatide (180/2/90) and
were administered, in a randomized fashion, either half (0.27 mg/kg) or
three-quarters (0.40 mg/kg) of the standard dose of tenecteplase (TNK).
After completion of Part 1, all patients in Part 2 (bottom, A) received
half-dose tenecteplase, whereas the second bolus dose of eptifibatide was
randomly assigned (90 vs. 180 g/kg). On the basis of the dose-finding
results, the combination of eptifibatide 180/2/180 plus half-dose tenect-
eplase was selected for direct comparison to standard-dose tenecteplase in
dose-confirmation (B). ACC/AHA  American College of Cardiology/
American Heart Association; TIMI 3  Thrombolysis In Myocardial
Infarction grade 3 flow.
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EPTIFIBATIDE AND TNK. Patients in dose-finding all re-
ceived double-bolus and an infusion of eptifibatide plus
reduced-dose TNK. Because this was the first trial investi-
gating this combination of therapies, the dose-finding phase
explored varying doses of both eptifibatide and reduced-
dose TNK in two sequential parts (Fig. 1A). In Part 1 of
dose-finding, all patients received eptifibatide 180 g/kg
bolus, 2 g/kg/min infusion, followed by a 90 g/kg bolus
10 min later (180/2/90), and were randomized to either
half-dose TNK (0.27 mg/kg) or three-quarter-dose TNK
(0.40 mg/kg). In Part 2 of dose-finding, all patients received
half-dose TNK and were randomized to one of two doses of
eptifibatide, 180/2/90 or 180/2/180 (Fig. 1B). The first
bolus doses of eptifibatide and TNK were administered
simultaneously, followed by initiation of the eptifibatide
infusion. The second bolus of eptifibatide was administered
10 min after the first. The eptifibatide infusion was reduced
to 1 g/kg/min in patients with renal dysfunction (creati-
nine 2 to 4 mg/dl; n  5), and could be reduced by 33% at
the investigator’s discretion in the case of mild bleeding (n
 18). The infusion continued for 18 to 24 h after coronary
intervention or 40 to 48 h in patients not undergoing early
percutaneous coronary intervention (PCI).
The combination of half-dose TNK (0.27 mg/kg) with
eptifibatide (180/2/180) was selected for direct comparison
with standard-dose (0.53 mg/kg) TNK monotherapy in the
dose-confirmation phase, after review of the totality of the
efficacy and safety data from the dose-finding phase (see the
Results section). Patients in the TNK monotherapy group
could receive adjunctive eptifibatide at the time of PCI at
the physician’s discretion (but not before 60 min), although
a single bolus (180/2) regimen was recommended in the first
24 h, owing to the limited safety experience available with
full-dose TNK plus glycoprotein IIb/IIIa inhibitor.
ANGIOGRAPHIC PROCEDURES. All patients underwent cor-
onary angiography 60 min (window 55 to 75 min) after
administration of the TNK bolus, which was considered
“Time 0.” Standardized views and techniques of injection as
developed by the Angiographic Core Laboratory were used
by the investigators. No additional heparin was adminis-
tered during diagnostic catheterization. Percutaneous coro-
nary intervention was permitted at the investigator’s discre-
tion after the 60-min angiogram. If PCI was performed,
additional weight-adjusted heparin boluses were adminis-
tered to achieve a target activated clotting time of 200 s in
patients receiving combination therapy and 250 s for TNK
monotherapy. Heparin use after the initial procedure was
not recommended but left to the discretion of the physician,
and the infusion was adjusted according to the aPTT.
CLINICAL PROCEDURES. Standard 12-lead electrocardio-
grams were obtained at presentation, before PCI at 60 min
(55 to 75 min), at 180 min (160 to 200 min), and at
discharge. Creatine kinase and creatine kinase-MB isoen-
zyme were obtained serially in the first 24 h, with recurrent
ischemia or after routine intervention, and daily for 5 days.
Complete blood and platelet counts were obtained at
baseline and at least once during the first 6 to 24 h. Patients
were assessed for clinical events through 30 days.
Study end points. EFFICACY. The primary efficacy end
point was the rate of TIMI grade 3 flow in the infarct-
related artery at 60 min as determined by the Angiographic
Core Laboratory, which was blinded to treatment assign-
ment. All angiograms were reviewed by a single reader
(C.M.G.) using previously established procedures to deter-
mine the TIMI flow grade (16), corrected Thrombolysis In
Myocardial Infarction frame count (cTFC) (17), and
Thrombolysis In Myocardial Infarction myocardial perfu-
sion grade (TMPG) (18). The angiographically evaluable
population consisted of patients who: 1) received some
quantity of study drugs (patients randomized to combina-
tion therapy also were required to receive the first boluses of
eptifibatide and TNK 15 min apart), and 2) had an
angiogram that was within the time window (55 to 75 min
post-TNK), before PCI, and of sufficient quality to permit
evaluation of TIMI epicardial flow. Prespecified secondary
angiographic end points included the distribution of flow
grades, cTFC, and TMPG at 60 and 90 min. The degree
(continuous value) of and occurrence of complete (i.e.,
70%) ST-segment resolution on the 12-lead electrocar-
diogram at 60 and 180 min compared with baseline were
also prespecified secondary efficacy end points. The electro-
cardiograms were read by the Electrocardiographic Core
Laboratory, blinded to treatment assignment, using previ-
ously established techniques (19).
Clinical efficacy end points using standardized definitions
(2) were analyzed for patients who received any study drug.
These included death, reinfarction, and urgent target vessel
revascularization (not including PCI performed immedi-
ately after the 60-min angiogram) through 48 h and 30
days, and severe pump failure through 30 days.
SAFETY. The primary safety end point was the rate of TIMI
major hemorrhage (2) (intracranial hemorrhage [ICH] or
clinically evident bleeding associated with a drop in hemo-
globin 5 g/dl accounting for transfusion), as determined
by an independent reviewer blinded to treatment assign-
ment. Other prespecified safety end points included the
rates of stroke, transfusions, and thrombocytopenia.
Statistical considerations. In dose-finding, a 40% rate of
TIMI grade 3 flow at 60 min with combination therapy was
selected as the lower boundary of interest given the previous
experience with alteplase and bolus fibrinolytics. A sample
size of 44 angiographically evaluable patients per cohort in
dose-finding provided 80% power for a one-sided test of
40% versus 60% of patients with TIMI grade 3 epicardial
flow at the   0.05 significance level.
In dose-confirmation, a sample size of 110 patients per
arm provided 81% power with a two-sided test at the 0.05
significance level to detect a 20% absolute difference in the
proportion of patients attaining TIMI grade 3 flow, assum-
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ing rates of 60% and 40% in the combination and mono-
therapy groups, respectively.
Statistical comparisons were made by chi-square analysis
(Cochran Mantel-Haenszel test stratified by infarct loca-
tion) for categorical variables, and a two-way analysis of
variance model fit to ranked data with infarct location,
treatment, and interaction effects for continuous variables,
in patient cohorts according to treatment received. Com-
parisons between treatment groups were considered explor-
atory in nature and were made without adjustment for
multiple comparisons. All tests were performed at the 0.05
significance level. We considered a p value of 0.05 to 0.10 a
“trend,” and a p value of 0.10 to 0.20 a “weak trend.”
RESULTS
A total of 438 patients were randomized, 189 in the dose-
finding phase and 249 in dose-confirmation. Twenty patients
did not receive any study drug, and one patient in dose-finding
did not receive eptifibatide; thus, 417 patients were evaluated
for clinical efficacy and safety events. An additional 47 patients
(angiogram outside the window: n 33 [7.5%]; no angiogram:
n  11 [2.5%]; other: n  3 [0.7%]) were excluded from the
angiographically evaluable cohort (n 370). Excluded patients
were equally distributed between the treatment groups. Base-
line characteristics are shown in Table 1. The mean duration of
eptifibatide infusion was 28.5  16.3 h, and the infusion was
terminated early because of bleeding in 8.7% of patients.
Adjunctive eptifibatide was administered in 42.9% of patients
in the TNK monotherapy arm undergoing PCI after ascer-
tainment of the primary end point.
Angiographic results. In the angiographically evaluable co-
hort, angiography was performed at a median of 61 min
(interquartile range 58 to 63 min). The rates of TIMI grade 3
flow at 60 min in the three combinations of eptifibatide and
reduced-dose TNK studied in dose-finding are shown in
Figure 2A. There was no difference in the rates of TIMI grade
3 flow (64% vs. 68%, p 0.69) or arterial patency (TIMI grade
2 or 3 flow: 77% vs. 79%, p  0.86) in dose-finding Part 1
comparing half-dose TNK with three-quarter-dose TNK in
combination with eptifibatide 180/2/90. Likewise, in Part 2 of
dose-finding, no difference in TIMI grade 3 flow rates was
observed when eptifibatide 180/2/90 was compared with 180/
2/180 in combination with half-dose TNK (65% vs. 67%, p
0.95). However, arterial patency was higher in the eptifibatide
180/2/180 group (84% vs. 96%, p  0.02). There were no
differences in the median cTFC or TMPG between the groups
(Table 2).
In the dose-confirmation phase, there was a slightly
higher rate of TIMI grade 3 flow at 60 min in patients
receiving combination therapy compared with TNK mono-
therapy (59% vs. 49%, p  0.15) (Fig. 2B), whereas there
was no difference in the median cTFC (35.9 vs. 40.0 frames,
p  0.54). In an analysis of all the available data with
half-dose TNK plus eptifibatide (180/2/180), the median
frame count was faster by 6 frames on average compared Ta
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Figure 2. Rates of Thrombolysis In Myocardial Infarction (TIMI) grade 2 and 3 flow in the infarct artery 60 min after administration of tenecteplase (TNK)
in dose-finding (A) and dose-confirmation (B). The last bar on the right in B represents pooled data for all patients receiving eptifibatide 180/2/180 and
half-dose TNK in both dose-finding and confirmation phases.
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with TNK monotherapy (Fig. 3). There was a weak trend
towards improved arterial patency rates at 60 min (85% vs.
77%, p  0.17), whereas the rates of TMPG grade 3 were
similar (49% vs. 45%, p  0.59).
12-lead electrocardiographic ST-segment resolution. In
the dose-finding phase, there were similar rates of ST-
segment resolution at 60 min (Table 2). All four groups
experienced high rates of ST-segment resolution by 180
min as assessed by the median degree of ST-segment
resolution (range 88% to 99%) and rate of complete (70%)
resolution (range 83% to 100%).
Combination therapy with eptifibatide 180/2/180 and
half-dose TNK exhibited a trend towards better ST-
segment resolution at 60 min than TNK monotherapy
(median degree of ST-segment resolution 71% vs. 61%, p
0.08; rate of complete ST-segment resolution 51% vs. 40%,
p  0.31). At 180 min, excluding those who had preceding
PCI, ST-segment resolution tended to favor combination
therapy (median 89% vs. 83%, p  0.28; complete ST-
segment resolution 79% vs. 58%, p  0.21), although the
differences were not statistically significant.
Composite assessment of epicardial and myocardial
reperfusion. In an exploratory analysis, combination ther-
apy achieved nearly twice the rate of optimal reperfusion
Table 2. Angiographic and Electrocardiographic Efficacy Data
Eptifibatide
Tenecteplase
Dose-Finding Phase
All Patients in
Dose-Finding
Dose-Confirmation PhasePart 1 Part 2
180/2/90
50%
180/2/90
75%
180/2/90
50%
180/2/180
50%
180/2/180
50%
—
100%
Angiogram evaluable, n 22 28 55 54 159 105 106
LAD infarct 7 (32%) 8 (29%) 21 (38%) 17 (32%) 53 (33%) 35 (33%) 35 (32%)
60 min
TIMI grade 3 14 (64%) 19 (68%) 36 (65%) 36 (67%) 105 (66%) 62 (59%) 52 (49%)
[95% CI] [40%, 83%] [48%, 84%] [51%, 78%] [53%, 79%] [58%, 73%] [49%, 69%] [39%, 59%]
cTFC 30.3 30.9 32.0 31.3 31.9 35.9 40.0
[25th, 75th percentiles] [21, 100] [24, 62] [23, 70] [24, 46] [23, 56] [24, 59] [22, 100]
TMP grade 3 13 (62%) 16 (57%) 29 (54%) 30 (56%) 88 (56%) 51 (49%) 48 (45%)
ST resolution evaluable, n 16 21 30 27 94 61 53
Median ST resolution 77% 79% 65% 75% 72% 71% 61%
[25th, 75th percentiles] [47%, 98%] [59%, 90%] [54%, 81%] [36%, 96%] [51%, 94%] [48%, 92%] [37%, 80%]
Complete (70%) 9 (56%) 11 (52%) 12 (40%) 15 (56%) 47 (50%) 31 (51%) 21 (40%)
180 min (excluding patients with
PCI before 180-min ECG)
ST resolution evaluable, n 4 5 12 15 36 33 26
Median ST resolution 88% 90% 93% 99% 92% 89% 83%
[25th, 75th percentiles] [85%, 92%] [87%, 91%] [86%, 96%] [76%, 100%] [87%, 98%] [76%, 97%] [57%, 97%]
Complete (70%) 4 (100%) 5 (100%) 10 (83%) 14 (93%) 33 (92%) 26 (79%) 15 (58%)
Data are shown as n (%) for dichotomous variables and median [25%, 75%] for continuous variables.
CI  confidence interval; cTFC  corrected TIMI frame count; ECG  electrocardiogram; LAD  left anterior descending; PCI  percutaneous coronary intervention;
TIMI  Thrombolysis In Myocardial Infarction; TMP  TIMI myocardial perfusion.
Figure 3. Corrected Thrombolysis In Myocardial Infarction (cTFC) frame count for all patients receiving half-dose tenecteplase (TNK) plus eptifibatide
(180/2/180) (dose-finding and dose-confirmation) versus TNK monotherapy (dose-confirmation only). The arrows correspond to the median cTFC for
combination therapy (34 frames) and TNK monotherapy (40 frames). As points of reference, 27 frames represents the accepted upper limit of cTFC for
Thrombolysis In Myocardial Infarction (TIMI) flow grade 3 in normal individuals, and 40 frames the breakpoint between TIMI flow grades 3 and 2. pts
 patients.
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(23% vs. 13%) among patients in whom all three outcomes
were assessed (Fig. 4). In the 43 patients (any treatment
regimen) with all three indicators of reperfusion success at
60 min, 30-day mortality was 0% and the rate of death,
reinfarction, or urgent target vessel revascularization was
2%.
Clinical efficacy. The overall rates of 30-day mortality
(5.0%) and reinfarction (2.4%) were low, thus the power to
detect differences was limited in this modestly sized phase II
study (Table 3). In dose-confirmation, the double end point
of death or reinfarction, and the triple composite of death,
reinfarction, or urgent target vessel revascularization tended
to be lower with combination therapy at 48 h (double end
point: 1.7% vs. 4.2%, p  0.25; triple end point: 3.4% vs.
11.0%, p  0.02), but these differences were not present at
30 days. Combination therapy tended to shorten the time to
elimination of chest pain after initiation of treatment by 36
min (p  0.11).
Safety. The overall rate of TIMI major hemorrhage in the
trial was 5.3% (occurring mostly [13/22] at the femoral
access site), with a weak trend towards more bleeding with
combination therapy than monotherapy in dose-
confirmation (7.6% vs. 2.5%, p  0.14) (Table 3). The only
two ICHs in dose-confirmation occurred in the TNK
monotherapy arm. Of the three major hemorrhages among
the 118 patients receiving TNK monotherapy, two occurred
early (within 2 h of randomization) among the 51 patients
who received adjunctive eptifibatide during PCI.
The rate of ICH among all 299 patients in the study
receiving any combination therapy was 1.0% (95% confi-
dence interval: 0.2% to 2.9%), whereas ICH occurred in
0.57% (95% CI: 0.01% to 3.1%) of the 176 patients who
received eptifibatide 180/2/180 and half-dose TNK, and in
1.7% (95% CI: 0.2% to 6.0%) of the 118 patients receiving
TNK monotherapy.
In dose-confirmation, combination therapy was associ-
ated with a higher rate of red cell transfusions (13.4% vs.
4.2%, p  0.02) and non-CABG related transfusions
(10.8% vs. 2.8%, p  0.03), consistent with the observed
increase rate of major non-cerebral bleeding.
DISCUSSION
This phase II study explored a new combination of platelet
glycoprotein IIb/IIIa inhibitor and reduced-dose fibrino-
lytic, and demonstrated modest improvements in surrogate
markers of epicardial and myocardial reperfusion, similar to
those noted in previous studies with combinations of abcix-
imab and either alteplase (2) or reteplase (3,4). Specifically,
in our study, the addition of double-bolus eptifibatide to
half-dose TNK tended to improve absolute rates of TIMI
grade 3 epicardial flow (10%), TMPG grade 3 flow
(4%), and median ST-segment resolution (10%) at 60
min compared with TNK monotherapy. These findings
support the hypothesis that potent platelet inhibition en-
hances thrombolysis and permits reduced doses of fibrino-
lytic drug to achieve at least similar angiographic and
electrocardiographic markers of efficacy compared with
standard fibrinolytic monotherapy. The INTEGRITI study
demonstrated that eptifibatide in combination with half-
dose TNK was associated with trends towards improved
epicardial and microcirculatory flow, thus extending the
previously reported improvement in angiographic results
with eptifibatide in combination with full-dose alteplase (9),
streptokinase (20), and half-dose alteplase (5).
Two recent large randomized trials (6,7) did not demon-
Figure 4. Rates of successful epicardial (i.e., Thrombolysis In Myocardial Infarction [TIMI] grade 3 flow) and myocardial (i.e., TIMI myocardial perfusion
grade 3 [TMPG 3], complete ST-segment resolution [STR]) reperfusion, and the combination of all three at 60-min resolution in all patients (dose-finding
and dose-confirmation) who received half-dose tenecteplase and eptifibatide 180/2/180 compared with patients treated with tenecteplase monotherapy (only
studied in dose-confirmation). TFG 3  TIMI flow grade 3.
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strate a reduction in mortality with the combination of
half-dose fibrinolytic and abciximab compared with fibrino-
lytic monotherapy. The reasons for the lack of mortality
reduction with combination therapy despite improvements
in several surrogate markers remain unclear. One potential
explanation is that the incremental benefit on TIMI grade 3
flow observed with combination therapy is insufficient
(pooled average 6.6% across all dose-confirmation phases of
phase II trials), and that clinically meaningful mortality
reduction (e.g., 1% absolute) would require on the order of
a 20% absolute increase in the rate of TIMI grade 3 flow
(21). Also, causes of death after acute myocardial infarction
(MI) are varied (e.g., shock, ICH, cardiac rupture, ventric-
ular arrhythmias, postoperative complications), and some of
these may not be favorably and/or significantly affected by
more potent pharmacologic reperfusion regimens. In addi-
tion, the increasing availability of primary PCI has resulted
in the enrollment of lower risk patients (e.g., fewer with
anterior MI) in recent trials of combination pharmacologic
therapy.
Nonetheless, reductions in ischemic complications of
acute MI are a desirable goal and could improve long-term
survival. The high-dose double-bolus plus infusion regimen
of eptifibatide used in this trial provides the additional
potential advantage that high-degree platelet inhibition is
not only achieved early, but also sustained for the duration
of the 18- to 48-h infusion (10); the latter is in contrast to
the standard abciximab bolus plus 12-h infusion regimen
which achieved 50% inhibition at 24 h (22). Such persis-
tent high-grade platelet inhibition may be particularly
relevant in patients who undergo delayed (i.e., after 12 to
24 h) PCI, and may translate into even greater prevention of
periprocedural and spontaneous recurrent ischemia/
infarction.
Safety. Increased rates of non-cerebral bleeding remain a
challenge to combination reperfusion regimens. Of note,
the 2.5% rate (95% confidence interval: 0.5% to 7.2%) of
major hemorrhage with tenecteplase monotherapy in our
study was unexpectedly low—less than the rates (4% to 9%)
observed in other recent phase II angiographic studies with
alteplase (2,23) and reteplase (3,4) monotherapy—but sim-
ilar to the rate (2.4%) observed with TNK and lower-dose
unfractionated heparin in a contemporaneous study (24).
Hence, further work is needed on several fronts to reduce
the risk of bleeding with combination therapy to improve
the risk-benefit relationship. These efforts include: identi-
fication of patients at higher risk of bleeding complications;
studying the utility of gastrointestinal prophylaxis in an
attempt to mitigate the increased rates observed in the larger
trials (6,7); exploring downward adjustment of concomitant
antithrombotic therapy (e.g., 30 U/kg heparin bolus, max-
imum 2,000 U) (2); and considering dose reduction of the
fibrinolytic, glycoprotein IIb/IIIa inhibitor, and antithrom-
bin in patients at high risk for bleeding and especially ICH
Table 3. Clinical Efficacy and Procedures (Through 30 Days) and Safety (Through Discharge*)
Eptifibatide
Tenecteplase
Dose-Finding Phase
All Patients in
Dose-Finding
Dose-Confirmation PhasePart 1 Part 2
180/2/90
50%
180/2/90
75%
180/2/90
50%
180/2/180
50%
180/2/180
50%
—
100%
Number of patients 28 29 65 58 180 119 118
Death 4 (14%) 1 (3%) 4 (6%) 2 (3%) 11 (6%) 4 (3%) 6 (5%)
Reinfarction 0 (0%) 1 (3%) 2 (3%) 3 (5%) 6 (3%) 4 (3%) 0 (0%)
Urgent revascularization 2 (7%) 2 (7%) 9 (14%) 8 (14%) 21 (12%) 7 (6%) 12 (10%)
CABG 2 (7%) 1 (3%) 6 (9%) 5 (9%) 14 (8%) 3 (3%) 4 (3%)
PCI 0 (0%) 1 (3%) 3 (5%) 3 (5%) 7 (4%) 4 (3%) 8 (7%)
Severe pump failure 4 (14%) 2 (7%) 3 (5%) 3 (5%) 12 (7%) 6 (5%) 6 (5%)
Time from TNK to symptom 1.3 0.8 1.1 0.7 0.9 1.0 1.6
resolution (h) [0.3, 2.6] [0.3, 2.7] [0.5, 2.7] [0.3, 1.8] [0.3, 2.4] [0.3, 1.9] [0.3, 2.9]
PCI
Any 19 (68%) 22 (76%) 41 (63%) 40 (69%) 122 (68%) 83 (70%) 90 (76%)
Early ( 2 h) 13 (40%) 21 (72%) 30 (46%) 30 (52%) 94 (52%) 61 (51%) 76 (64%)
Delayed 6 (21%) 3 (10%) 11 (17%) 14 (24%) 34 (19%) 24 (20%) 20 (17%)
CABG 8 (29%) 2 (7%) 8 (13%) 9 (14%) 27 (15%) 8 (7%) 11 (9%)
Major hemorrhage 4 (14%) 1 (3%) 1 (2%) 4 (7%) 10 (6%) 9 (8%) 3 (3%)
Intracranial 0 (0%) 1† (3%) 1‡ (2%) 1 (2%) 3 (2%) 0 (0%) 2§ (2%)
Spontaneous 0 (0%) 0 (0%) 0 (0%) 1 (2%) 1 (0.6%) 3¶ (3%) 0 (0%)
Instrumented 4 (14%) 0 (0%) 0 (0%) 2 (3%) 6 (3%) 6 (5%) 1 (0.8%)
Minor hemorrhage 6 (21%) 9 (31%) 11 (17%) 6 (10%) 32 (18%) 37 (31%) 18 (15%)
Transfusions
PRBC 8 (29%) 3 (10%) 5 (8%) 6 (10%) 22 (12%) 16 (13%) 5 (4%)
Platelets 3 (11%) 1 (3%) 0 (0%) 1 (2%) 4 (2%) 3 (2%) 1 (1%)
Platelets  50,000/mm3 1 (4%) 0 (0%) 0 (0%) 0 (0%) 1 (0.6%) 1 (0.9%) 0 (0%)
*Or day 5, whichever came first. †Cerebral amyloid angiopathy diagnosed at autopsy; received twice the protocol heparin infusion rate. ‡Received 50 mg tenecteplase instead of
20 mg. §One patient received 50 mg tenecteplase instead of 30 mg; the second patient received adjunctive eptifibatide for PCI. Gastrointestinal. ¶Two gastrointestinal, one
respiratory.
CABG  coronary artery bypass graft surgery; PCI  percutaneous coronary intervention; PRBC  packed red blood cell; TNK  tenecteplase.
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(e.g., age 75 years, low body weight, female gender). Use
of low-molecular-weight heparin in combination with fi-
brinolytic and glycoprotein IIb/IIIa inhibitor, such as re-
cently studied in the Enoxaparin Antithrombin Therapy for
ST-Elevation (ENTIRE)-TIMI 23 trial (24), also should
be investigated.
Study limitations. The optimal surrogate markers of
reperfusion and their relationship to clinical outcomes in the
modern era, which includes more frequent early revascular-
ization, remain to be established. This modest-sized phase
II study investigated patients at lower risk (age 75 years,
hemodynamically stable, lower rate of anterior MI) com-
pared with patients enrolled in fibrinolytic megatrials and
large registries, resulting in low rates of clinical events. We
did not adjust for multiple group comparisons, which
increases the likelihood that some of the observed differ-
ences may be due to the play of chance. Lastly, 11% of
patients receiving therapy had angiograms that were con-
sidered unevaluable for the primary analysis; however, in-
clusion of the data from all patients with angiography did
not result in a meaningful change in the results.
Future directions. The data from the INTEGRITI study
suggest that eptifibatide and half-dose TNK is a potentially
useful combination for acute MI, and additional studies are
planned. Although a total of more than 20,000 patients
have been studied in the two large trials performed to date,
several important issues need to be addressed before com-
bination therapy can be recommended for widespread im-
plementation. The efficacy and safety of various combina-
tions of glycoprotein IIb/IIIa inhibitor, fibrinolytic, and
antithrombin should not be assumed equal to one another
based on presumed similar class effects—instead, each
unique combination requires careful assessment. Patients at
high risk for bleeding deserve particular attention, and
evaluation of reduced doses of one or more of the elements
of the combination regimen versus using other strategies to
achieve reperfusion (e.g., primary PCI) in these patients
should be undertaken. Given the proven benefit of high-
grade platelet inhibition with glycoprotein IIb/IIIa inhibi-
tors in the setting of PCI, and a recent analysis demonstrat-
ing significantly reduced mortality in patients with TIMI
grade 3 flow before mechanical reperfusion (25), the role of
combination therapy followed by PCI, compared with
existing standards of practice (primary PCI, fibrinolytic
monotherapy) also deserves further investigation. Because
only 23% of patients in our trial had TIMI grade 3 flow plus
TMPG grade 3 plus complete ST-segment resolution
despite an extremely vigorous antiplatelet regimen, better
methods of reperfusion, whether pharmacologic or mechan-
ical or some combination of both, will need to be developed.
Conclusions. This randomized, controlled, open-label,
phase II angiographic trial demonstrated that double-bolus
eptifibatide (180/2/180) plus half-dose TNK tended to
improve angiographic flow and ST-segment resolution
compared with TNK monotherapy but was associated with
more transfusions and non-cerebral bleeding. Further study
is needed before this combination can be recommended for
general use.
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Klinikum Kassel, Kassel, Germany: European co-
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TIMI Angiographic Core Laboratory, Harvard Clinical
Research Institute, Boston, MA: Principal investigator: C.
Michael Gibson; Director: Susan J. Marble; Quantitative
angiography technician: Nicole Kraimer; Data manager:
Sabina Murphy.
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Group, Boston, MA: 12-lead ECG ST-segment resolution.
Director: David A. Morrow. Co-directors: Marc S. Saba-
tine, Howard A. Cooper, Graham C. Wong. Administra-
tive assistant: Betsy Walsh.
Ischemia Monitoring Core Laboratory, Duke Clinical
Research Institute, Durham, NC: Continuous 12-lead
ECG ST-segment analysis. Director: Mitchell W. Krucoff.
Co-Director: Cynthia L. Green. Project leader: Kathleen
Trollinger.
Cardiac Marker Core Laboratory, TIMI Study Group,
Boston, MA: Director: David A. Morrow. Lab director:
Nadar Rifai.
Receptor Occupancy Core Laboratory, University of
Tennessee-Memphis, Memphis, TN: Director: Lisa K.
Jennings. Project manager: Mary V. Jacoski. Lead technol-
ogists: Shila Cholera, Rajini Krishnan.
Pharmacokinetics Core Laboratory, Phoenix Interna-
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RITI clinical centers and the Angiographic Core
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CLINICAL CENTERS IN ORDER OF NUMBER OF
PATIENTS ENROLLED (PRINCIPAL INVESTIGATOR IS
FIRST INDIVIDUAL LISTED)
U.S. (217 patients). St. Paul Heart Clinic, St. Paul, MN:
Principal investigator, Kenneth W. Baran; Research coor-
dinators, Barb Bruhn-Ding, Patti Filkins, Beth Jorgenson,
Cheryl Iaccarella. Baystate Medical Center, Springfield,
MA: Principal investigator, Marc J. Schweiger; Research
coordinator, Deborah Warwick. Lutheran Medical Center,
Wheat Ridge, CO: Principal investigator, Jerry Miklin;
Research coordinator, Linda McFadden. Montefiore Med-
ical Center, Bronx, NY: Principal investigators, Mark
Greenberg, Hiltrud Mueller; Research coordinator, Anne-
marie Logan. Robert Wood Johnson Medical School, New
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Research coordinator, Laurie Casazza. Thunderbird Samar-
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Medical Center, Portland, ME: Principal investigator, Cos-
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Research coordinators, Teri Harbour, Tracey Gerez. Metro
Health Medical Center, Cleveland, OH: Principal investi-
gator, Thomas Vrobel; Research coordinator, Linda Ver-
rilli. Peninsula Regional Medical Center, Salisbury, MD:
Principal investigator, Steven Hearne; Research coordina-
tor, Virginia Seefried. Riverside Community Hospital, Riv-
erside, CA: Principal investigator, Chiayu Chen; Research
coordinator, Valerie Whyte. University Hospital, Augusta,
GA: Principal investigator, A. Bleakley Chandler; Research
coordinator, Paula Easler. Birmingham Heart Clinic, Bir-
mingham, AL: Principal investigator, Robert Foster; Re-
search coordinator, April Snow. High Point Regional
Health System, High Point, NC: Principal investigator,
Steven Rohrbeck; Research coordinator, Tami Hedrick. San
Jose Medical Center, San Jose, CA: Principal investigator,
K. Kam Tabari; Research coordinator, Melinda Savella.
Cardiology Consultants of Napa Valley, Napa Valley, CA:
Principal investigator, Andrew Wong; Research coordina-
tor, Wendy Neustrup. Eastern Maine Medical Center,
Bangor, ME: Principal investigator, Peter VerLee; Research
coordinator, Cindy Whited. Gaston Memorial Hospital,
Gastonia, NC: Principal investigator, Marc Silver; Research
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ter, Fort Lauderdale, FL: Principal investigator, John Bra-
den; Research coordinator, Mary Lou Kompa. St. Eliza-
beth’s Hospital, Belleville, IL: Principal investigator,
Richard Hui; Research coordinator, Donna Mann. Univer-
sity of California at San Francisco, San Francisco, CA:
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KS: Principal investigator, Steven Bloom; Research coordi-
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Center, Boston, MA: Principal investigator, Douglas W.
Losordo; Research coordinator, Laura Kenney. University
Hospital of Arkansas, Little Rock, AR: Principal investiga-
tor, Jorge Saucedo; Research coordinator, Harisha Patel.
Los Angeles County/USC Medical Center, Los Angeles,
CA: Principal investigator, Anilkumar Mehra; Research
coordinator, Pooya Ataii.
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Siegen: Principal investigator, Peter Schuster; Research
coordinator, Hans-Peter Hobbach. Klinikum Kassel, Ger-
many: Principal investigator, Uwe Zeymer; Research coor-
dinator, Stefan Gesing. Krankenhaus Dresden-
Friedrichstadt, Dresden: Principal investigator, Ernst
Altman: Research coordinators, Andreas Graf, Jochen
Eberhard. Krankenhaus Neukoelln, Berlin: Principal inves-
tigator, Zdzislaw F. Forycki; Research coordinator, Lorenz
Reill. Medizinische Klinik II-Klinikum Bayreuth, Bay-
reuth: Principal investigator, Wolfgang Maeurer; Research
coordinators, Burkhard Jaeger, Stephen Korzeniowski.
Marien Hospital, Wesel: Principal investigator, Klaus-
Theodor Haerten; Research coordinator, Bernd Artmeyer.
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mann. Med. Klinik Berlin Charite, Berlin: Principal
investigator, Heinz Theres; Research coordinators, Mi-
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Friedrich Voehringer; Research coordinator, Joerg
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fenbach, Offenbach: Principal investigator, Ernst Girth;
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Research coordinator, Margaret Tychon. University Hospi-
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